Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about DCOY, unsubscribe in one click. Privacy
DCOY holds $8.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 35 · Moderate
The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DCOY files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DCOY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →